Current status of N-NOSE testing and employee rewards with lump-sum payments amid COVID-19 crisis


Although we take the Government’s state of emergency seriously, in order not to pause our first cancer screening test N-NOSE completely, we continue the analysis in our analysis center and three R&D centers while taking necessary steps to prevent infection.

To support our employees to cope with the situation, we have decided to reward them with lump-sum payments (JPY 30,000 per employee).

We will continue to focus on our efforts to expand N-NOSE tests so that we can provide it for as many people as possible.